Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
There is an exponentially growing interest in targeting immune checkpoint molecules in breast cancer, particularly in the triple-negative subtype where unmet treatment needs remain. This study was designed to analyze the expression, localization and prognostic role of PD-1, PD-L1, PD-L2, CTLA-4, LAG3 and TIM3 in primary breast cancer. Gene expression analysis using the METABRIC microarray dataset found that all six immune checkpoint molecules are highly expressed in basal-like and HER2-enriched compared to the other breast cancer molecular subtypes. Flow cytometric analysis of fresh tissue homogenates from untreated primary tumors show that PD-1 is principally expressed on CD4+ or CD8+ T cells and CTLA-4 on CD4+ T cells. The global proportion of PD-L1+, PD-L2+, LAG3+ and TIM3+ tumor infiltrating lymphocytes was low and detectable in only a small number of tumors. Immunohistochemically staining fixed tissues from the same tumors was employed to score tumor infiltrating lymphocytes and tertiary lymphoid structures. PD-L1+, PD-L2+, LAG3+ and TIM3+ cells were detected in some tertiary lymphoid structures in a pattern that resembles secondary lymphoid organs. This observation suggests that tertiary lymphoid structures are important sites of immune activation and regulation, particularly in tumors with extensive baseline immune infiltration. Significantly improved overall survival was correlated with PD-1 expression in the HER2-enriched and PD-L1 or CTLA-4 expression in basal-like breast cancer. PD-1 and CTLA-4 proteins were most frequently detected on tumor infiltrating lymphocytes, which supports the correlations observed between their gene expression and improved long term outcome in basal-like and HER2-enriched breast cancer. PD-L1 expression by tumor or immune cells is uncommon in breast cancer. Overall, the data presented here distinguish PD-1 as a marker of T cell activity in both the T and B cell areas of breast cancer associated tertiary lymphoid structures. We found that immune checkpoint molecule expression parallels the extent of tumor infiltrating lymphocytes and tertiary lymphoid structures, although there is a noteworthy amount of heterogeneity between tumors even within the same molecular subtype. These data indicate that assessing the levels of immune checkpoint molecule expression in an individual patient has important implications for the success of therapeutically targeting them in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Intraclass correlations: Uses in assessing rater reliability.
Shrout, P. E., & Fleiss, J. L. (1979) · Psychological Bulletin · doi:10.1037/0033-2909.86.2.420 · Cited by 24,532
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · cited 5×
“infiltrating Primary Bc Gene expression analysis using the METABRIC dataset (37) reveals that LAG3 is more frequently detected in the basal-like compared with the other subtypes and in the HER2-enriched BC subtype compared with luminal A/B and normal-like; in luminal B compared to luminal A; and in normal-like compare…”
BackgroundMethodResultInfluentialElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 2×
“This analysis was undertaken to (1) correlate their expression in the BC molecular subtypes; (2) associate specific BC cellular subpopulations with clinicopathological data; (3) situate their location in the tumor microenvironment; and (4) correlate their presence with BC prognosis.”
BackgroundMolecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 1×
“While a functional role for these CD8+ T cell subpopulations is currently unknown, CD8+PD-1int TIL are thought to be more responsive to PD-1 or PD-L1 blocking agents (55).”
BackgroundAhmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023 · cited 2×
“These data also reveal a contrast between BC and solid tumor types where checkpoint molecules are frequently expressed on tumor cells, such as melanoma, renal, and lung cancer (16, 17).”
BackgroundResultTim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695 · cited 1×
“These data are supported by several studies, including an analysis of >100 treatment naïve BC patients where Treg abundance in the tumor microenvironment was characterized by high levels of surface CCR8, CTLA-4, and PD-1 (69).”
Result
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer
Garaud, S., Buisseret, L., Solinas, C., Gu-Trantien, C., de Wind, A., Van den Eynden, G., Naveaux, C., Lodewyckx, J.-N., Boisson, A., Duvillier, H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129641 · Cited by 347
Self-citationEl Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00346-1 · Cited by 268
Self-citationBiomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
“Physiologically relevant PD-L1 expression in some cases may be spatially distinct from the tumor mass and present in structures such as tertiary lymphoid structures or draining lymph nodes that may not be routinely sampled or assayed (Behr et al. 2014, Solinas et al. 2017).”
BackgroundRapoport, B. L., Nayler, S., Mlecnik, B., Smit, T., Heyman, L., Bouquet, I., Martel, M., Galon, J., Benn, C.-A., & Anderson, R. (2022) · Cancers · doi:10.3390/cancers14102525 · Cited by 33
Jennewein, L., Bartsch, G., Gust, K., Kvasnicka, H., Haferkamp, A., Blaheta, R., Mittelbronn, M., Harter, P., & Mani, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8597 · Cited by 27
“We used tonsil material on every single tissue micro array as a positive control as described in literature before (31-38).”
Metadata
- Authors
- Solinas, C., Garaud, S., De Silva, P., Boisson, A., Van den Eynden, G., de Wind, A., Risso, P., Rodrigues Vitória, J., Richard, F., Migliori, E., Noël, G., Duvillier, H., Craciun, L., Veys, I., Awada, A., Detours, V., Larsimont, D., Piccart-Gebhart, M., & Willard-Gallo, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-10-30
- Volume
- 8
- Pages
- 1412-1412
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2765492972
- Cited by
- 106
- References
- 11
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.